Pharmacokinetic data from this trial demonstrated that in comparison to the nonliposomal drug, the liposomal formulation OSI-7904L halteredredispositionon properties and exhibited a longer plasma circulation time.
Importantly, data from this trial demonstrated, for the first time, that systemically delivered siRNA can reduce protein levels of a specific gene through an RNAi mechanism in humans [ 264].
Data from this trial demonstrated almost double the number of children showing a 4-fold or 2-fold boosted antibody response when vaccinated via the inflatable bag than by injection.
Data from this trial demonstrated that BMI does not influence the efficacy of tamoxifen with respect to breast cancer recurrence and mortality after breast cancer events (Dignam et al, 2003).
The basis for adjuvant treatment of stage IIB, IIC, or III disease with IFN-α rests on a randomized, multicenter, national trial, E1684, that was conducted by the Eastern Cooperative Oncology Group in 1995 (n=287). 5 Data from this trial demonstrated significantly improved relapse-free survival (RFS) and OS with the use of adjuvant HDI in patients with non-metastatic but locally advanced melanoma.
Data from these trials demonstrated the consistent performance of these lines, validating the effectiveness of SUB1 in conferring tolerance of submergence, independent of the genetic background of the recipient variety or the environment where it is grown.
The radiographic data from the AIM trial demonstrate a slowing of joint erosion by about 50% after 1 year of abatacept treatment compared with placebo.
The data from the VISION trial demonstrate a favourable ocular and systemic safety profile for 3 years of continuous selective VEGF inhibition with pegaptanib sodium for the treatment of NV-AMD.
The most recent data from this trial even demonstrated a benefit of intensive treatment of blood glucose on cardiovascular disease, an effect that persisted many years after the formal study ended.
Taken together, the data from the current trial demonstrates that high lysine transgenic rice led to no adverse effect in Sprague-Dawley rats given a diet containing up to 70% HFL1 rice in 90 days.
